Pfizer and the Medicines Patent Pool sign a global licensing agreement that will allow Pfizer's experimental COVID-19 oral drug Paxlovid to be manufactured under a royalty-free license in 95 low and middle-income countries. (The Wall Street Journal) COVID-19 drug developmentCOVID-19 pandemic link embed save